Hua LH - Search Results

1

Multiple sclerosis management during the COVID-19 pandemic.

Moss BP, Mahajan KR, Bermel RA, Hellisz K, Hua LH, Hudec T, Husak S, McGinley MP, Ontaneda D, Wang Z, Weber M, Tagliani P, Cárdenas-Robledo S, Zabalza A, Arrambide G, Carbonell-Mirabent P, Rodríguez-Barranco M, Sastre-Garriga J, Tintore M, Montalban X, Douglas M, Ogbuokiri E, Aravidis B, Cohen JA, Mowry EM, Fitzgerald KC. Moss BP, et al. Among authors: hua lh. Mult Scler. 2020 Sep;26(10):1163-1171. doi: 10.1177/1352458520948231. Epub 2020 Aug 10. Mult Scler. 2020. PMID: 32772807 Free PMC article.

2

Considerations in the development of generic disease therapies for multiple sclerosis.

Hua LH, Cohen JA. Hua LH, et al. Neurol Clin Pract. 2016 Aug;6(4):369-376. doi: 10.1212/CPJ.0000000000000267. Neurol Clin Pract. 2016. PMID: 27574572 Free PMC article. Review.

3

Therapeutic Targets for Multiple Sclerosis: Current Treatment Goals and Future Directions.

Smith AL, Cohen JA, Hua LH. Smith AL, et al. Among authors: hua lh. Neurotherapeutics. 2017 Oct;14(4):952-960. doi: 10.1007/s13311-017-0548-5. Neurotherapeutics. 2017. PMID: 28653282 Free PMC article. Review.

4

Multiple Sclerosis: Unprecedented Progress But Significant Challenges Ahead.

Conway DS, Hua LH, Cohen JA. Conway DS, et al. Among authors: hua lh. Neurotherapeutics. 2017 Oct;14(4):832-834. doi: 10.1007/s13311-017-0576-1. Neurotherapeutics. 2017. PMID: 28956322 Free PMC article. No abstract available.

5

Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60.

Hua LH, Fan TH, Conway D, Thompson N, Kinzy TG. Hua LH, et al. Mult Scler. 2019 Apr;25(5):699-708. doi: 10.1177/1352458518765656. Epub 2018 Mar 20. Mult Scler. 2019. PMID: 29557704

6

Changes in patient-reported outcomes between continuers and discontinuers of disease modifying therapy in patients with multiple sclerosis over age 60.

Hua LH, Harris H, Conway D, Thompson NR. Hua LH, et al. Mult Scler Relat Disord. 2019 May;30:252-256. doi: 10.1016/j.msard.2019.02.028. Epub 2019 Mar 1. Mult Scler Relat Disord. 2019. PMID: 30851638

7

Corrigendum to "Changes in patient-reported outcomes between continuers and discontinuers of disease modifying therapy in patients with multiple sclerosis over age 60" [Multiple Sclerosis and Related Disorders 30 (2019) 252-256].

Hua LH, Harris H, Conway D, Thompson NR. Hua LH, et al. Mult Scler Relat Disord. 2019 May;30:293. doi: 10.1016/j.msard.2019.03.013. Epub 2019 Mar 26. Mult Scler Relat Disord. 2019. PMID: 30987754 No abstract available.

8

Duration of natalizumab therapy and reasons for discontinuation in a multiple sclerosis population.

Conway DS, Hersh CM, Harris HC, Hua LH. Conway DS, et al. Among authors: hua lh. Mult Scler J Exp Transl Clin. 2020 Jan 27;6(1):2055217320902488. doi: 10.1177/2055217320902488. eCollection 2020 Jan-Mar. Mult Scler J Exp Transl Clin. 2020. PMID: 32064117 Free PMC article.

9

Comparative effectiveness studies in multiple sclerosis.

Hersh CM, Hua LH. Hersh CM, et al. Among authors: hua lh. Neurodegener Dis Manag. 2020 Jun;10(3):113-118. doi: 10.2217/nmt-2020-0015. Epub 2020 Jun 5. Neurodegener Dis Manag. 2020. PMID: 32501735 No abstract available.

10

Outcomes and future directions for neuroimmunology/multiple sclerosis fellowship training: Survey of recent trainees.

Hua LH, Obeidat AZ, Longbrake EE. Hua LH, et al. Mult Scler Relat Disord. 2020 Sep;44:102296. doi: 10.1016/j.msard.2020.102296. Epub 2020 Jun 10. Mult Scler Relat Disord. 2020. PMID: 32585616 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

40 results

Search Page